AR080249A1 - Compuestos en calidad de antagonistas de bradiquinina-b1 - Google Patents
Compuestos en calidad de antagonistas de bradiquinina-b1Info
- Publication number
- AR080249A1 AR080249A1 ARP110100542A ARP110100542A AR080249A1 AR 080249 A1 AR080249 A1 AR 080249A1 AR P110100542 A ARP110100542 A AR P110100542A AR P110100542 A ARP110100542 A AR P110100542A AR 080249 A1 AR080249 A1 AR 080249A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- bradiquinina
- antagonist
- compounds
- quality compounds
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 239000005557 antagonist Substances 0.000 title 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 3
- JNCMHMUGTWEVOZ-UHFFFAOYSA-N F[CH]F Chemical compound F[CH]F JNCMHMUGTWEVOZ-UHFFFAOYSA-N 0.000 abstract 2
- 108010081348 HRT1 protein Hairy Proteins 0.000 abstract 2
- 102100021881 Hairy/enhancer-of-split related with YRPW motif protein 1 Human genes 0.000 abstract 2
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- 125000002993 cycloalkylene group Chemical group 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 125000004430 oxygen atom Chemical group O* 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C211/00—Compounds containing amino groups bound to a carbon skeleton
- C07C211/43—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
- C07C211/54—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having amino groups bound to two or three six-membered aromatic rings
- C07C211/56—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having amino groups bound to two or three six-membered aromatic rings the carbon skeleton being further substituted by halogen atoms or by nitro or nitroso groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D307/18—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Su preparacion, los medicamentos que contienen los compuestos farmacologicamente eficaces, su preparacion y su uso. Reivindicacion 1: Compuestos caracterizados porque tienen la formula general (1) en la cual: R1 es el grupo de formula (2); R2 significa H o -CH3; R3 y R4, junto con el átomo de carbono al que están unidos, un grupo cicloalquileno C3-6, en el que una unidad -CH2 puede estar reemplazada por un átomo de oxígeno; R5 es H o -CH3; R6 es H, F, Cl o metilo; R7 es H, F, Cl, Br, -CN, alquilo C1-4, CF3, CHF2; R8 es H; R9 es F, Cl, Br, alquilo C1-4, -O-alquilo C1-4, -S-alquilo C1-4; R10 es H; R11 es F, Cl, Br, -CN, alquilo C1-4, CF3, CHF2; y X es CH o N; sus enantiomeros, sus diastereoisomeros, sus mezclas y sus sales.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/EP2010/052232 WO2010097372A1 (de) | 2009-02-26 | 2010-02-23 | Verbindungen als bradykinin-b1-antagonisten |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR080249A1 true AR080249A1 (es) | 2012-03-21 |
Family
ID=43981434
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP110100542A AR080249A1 (es) | 2010-02-23 | 2011-02-22 | Compuestos en calidad de antagonistas de bradiquinina-b1 |
Country Status (22)
| Country | Link |
|---|---|
| EP (1) | EP2539323B3 (es) |
| JP (1) | JP5603955B2 (es) |
| KR (1) | KR101843341B1 (es) |
| CN (2) | CN102781916B (es) |
| AP (1) | AP3218A (es) |
| AR (1) | AR080249A1 (es) |
| AU (1) | AU2011219885C1 (es) |
| CA (1) | CA2790952C (es) |
| CY (1) | CY1116182T1 (es) |
| DK (1) | DK2539323T6 (es) |
| ES (1) | ES2531663T7 (es) |
| IL (1) | IL220680A (es) |
| MA (1) | MA34008B1 (es) |
| MX (1) | MX2012009224A (es) |
| NZ (1) | NZ601194A (es) |
| PE (1) | PE20121805A1 (es) |
| PL (1) | PL2539323T6 (es) |
| PT (1) | PT2539323E (es) |
| SG (1) | SG183336A1 (es) |
| SI (1) | SI2539323T1 (es) |
| TW (1) | TWI499589B (es) |
| WO (1) | WO2011104203A1 (es) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102007034620A1 (de) | 2007-07-25 | 2009-01-29 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue B1-Antagonisten |
| WO2009027450A1 (de) | 2007-08-29 | 2009-03-05 | Boehringer Ingelheim International Gmbh | Neue bradykinin b1-antagonisten |
| AU2011219885C1 (en) | 2010-02-23 | 2017-06-29 | Boehringer Ingelheim International Gmbh | Compounds as bradykinin B1 antagonists |
| US8937073B2 (en) | 2010-08-20 | 2015-01-20 | Boehringer Ingelheim International Gmbh | Disubstituted tetrahydrofuranyl compounds and their use as B1-receptor antagonists |
| EP2606043B1 (de) * | 2010-08-20 | 2014-07-09 | Boehringer Ingelheim International GmbH | Pyridazinderivative als bradykinin b1 rezeptor antagonsiten |
| JP7376582B2 (ja) * | 2018-10-22 | 2023-11-08 | イーオーイー オレオ ゲーエムベーハー | 成形体への圧縮を目的とした粉末材料用添加剤 |
| MX2021007970A (es) * | 2019-01-04 | 2021-08-16 | Jiangsu Hengrui Medicine Co | Derivado de 6-oxo-1,6-dihidropiridazina, metodo de preparacion del mismo y uso medico del mismo. |
| TW202102480A (zh) * | 2019-02-20 | 2021-01-16 | 大陸商江蘇恆瑞醫藥股份有限公司 | ６－側氧基－１，６－二氫噠嗪類前藥衍生物、其製備方法及其在醫藥上的應用 |
| WO2021198534A1 (en) | 2020-04-04 | 2021-10-07 | Oxurion NV | Plasma kallikrein inhibitors for use in the treatment of coronaviral disease |
| WO2023148016A1 (en) | 2022-02-04 | 2023-08-10 | Oxurion NV | Biomarker for plasma kallikrein inhibitor therapy response |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR038377A1 (es) * | 2002-02-08 | 2005-01-12 | Merck & Co Inc | Derivados de n-bifenil-aminocicloalcancarboxamida (con sustitucion con metilo) |
| US7163951B2 (en) * | 2002-08-29 | 2007-01-16 | Merck & Co., Inc. | N-biarylmethyl aminocycloalkanecarboxamide derivatives |
| WO2005016886A1 (en) * | 2003-08-07 | 2005-02-24 | Merck & Co., Inc. | Sulfonyl substituted n-(biarylmethyl) aminocyclopropanecarboxamides |
| JP2007526311A (ja) * | 2004-03-02 | 2007-09-13 | メルク エンド カムパニー インコーポレーテッド | ブラジキニンアンタゴニストとしてのアミノシクロプロパンカルボキサミド誘導体 |
| CN101171005A (zh) | 2005-05-11 | 2008-04-30 | 尼科梅德有限责任公司 | Pde4抑制剂罗氟司特与四氢生物蝶呤衍生物的组合 |
| HUP0600809A3 (en) * | 2006-10-27 | 2008-09-29 | Richter Gedeon Nyrt | New phenylsulfamoyl-benzamide derivatives as bradykinin antagonists, process and intermediates for their preparation and pharmaceutical compositions containing them |
| AP2011005808A0 (en) * | 2009-02-26 | 2011-08-31 | Boehringer Ingelheim Int | Compounds as bradykinin B1 antagonists. |
| AU2011219885C1 (en) | 2010-02-23 | 2017-06-29 | Boehringer Ingelheim International Gmbh | Compounds as bradykinin B1 antagonists |
-
2011
- 2011-02-21 AU AU2011219885A patent/AU2011219885C1/en not_active Ceased
- 2011-02-21 PT PT117058586T patent/PT2539323E/pt unknown
- 2011-02-21 JP JP2012553341A patent/JP5603955B2/ja active Active
- 2011-02-21 NZ NZ601194A patent/NZ601194A/en not_active IP Right Cessation
- 2011-02-21 MX MX2012009224A patent/MX2012009224A/es active IP Right Grant
- 2011-02-21 EP EP11705858.6A patent/EP2539323B3/de active Active
- 2011-02-21 KR KR1020127021929A patent/KR101843341B1/ko not_active Expired - Fee Related
- 2011-02-21 CA CA2790952A patent/CA2790952C/en not_active Expired - Fee Related
- 2011-02-21 WO PCT/EP2011/052512 patent/WO2011104203A1/de not_active Ceased
- 2011-02-21 MA MA35153A patent/MA34008B1/fr unknown
- 2011-02-21 PL PL11705858T patent/PL2539323T6/pl unknown
- 2011-02-21 ES ES11705858.6T patent/ES2531663T7/es active Active
- 2011-02-21 AP AP2012006330A patent/AP3218A/xx active
- 2011-02-21 SI SI201130402T patent/SI2539323T1/sl unknown
- 2011-02-21 SG SG2012060620A patent/SG183336A1/en unknown
- 2011-02-21 DK DK11705858.6T patent/DK2539323T6/en active
- 2011-02-21 CN CN201180009563.1A patent/CN102781916B/zh not_active Expired - Fee Related
- 2011-02-21 CN CN201410206948.2A patent/CN103980258B/zh not_active Expired - Fee Related
- 2011-02-21 PE PE2012001250A patent/PE20121805A1/es not_active Application Discontinuation
- 2011-02-22 AR ARP110100542A patent/AR080249A1/es not_active Application Discontinuation
- 2011-02-22 TW TW100105851A patent/TWI499589B/zh active
-
2012
- 2012-06-28 IL IL220680A patent/IL220680A/en not_active IP Right Cessation
-
2015
- 2015-03-02 CY CY20151100211T patent/CY1116182T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR080249A1 (es) | Compuestos en calidad de antagonistas de bradiquinina-b1 | |
| ES2621140T3 (es) | Compuestos ácido acilamino y preparaciones alimenticias que los contienen | |
| AR102361A1 (es) | Compuestos de metil-quinolina útiles para inhibir la sintasa-1 de prostaglandina microsomal e2 | |
| PA8852101A1 (es) | Nucleótidos uracil ciclopropílicos | |
| CY1119049T1 (el) | Υποκατεστημενα πυρρολιδινο-2-καρβοξαμιδια | |
| CL2012000999A1 (es) | Compuestos derivados de pirazoloespirocetona sustituida, inhibidores de acetil-coa carboxilasa; composicion farmaceutica que los comprende; uso para tratar o retrasar la progresion o el inicio de diabetes tipo 2, higado graso no alcoholico (hgna) o la resistencia hepatica a la insulina. | |
| PE20150400A1 (es) | Benzamidas n-sustituidas y su uso en el tratamiento del dolor | |
| AR081058A1 (es) | Derivados de arilmetoxi isoindolina, composiciones que los comprenden y su uso en el tratamiento del cancer. | |
| AR078278A1 (es) | Antagonistas de la tiazol y oxazol hepcidina, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de anemias y enfermedades asociadas a deficiencias de hierro. | |
| CL2012001911A1 (es) | Compuestos derivados de fumarato; composicion farmaceutica que los comprende; y su uso en el tratamiento de una enfermedad inflamatoria o neurodegenerativa. | |
| ES2626555T3 (es) | Pyridone amides como moduladores de canales de sodio | |
| ECSP12012293A (es) | Ciertas amino-pirimidinas, composicioines de las mismas y métodos para el uso de los mismos | |
| UY32490A (es) | Inhibidores de beta-secretasa | |
| AR082101A1 (es) | Acidos de hidroxifenilhexinoico ariloxialquileno-sustituido, procedimiento para su preparacion y su uso como medicamento | |
| AR073136A1 (es) | Compuestos de pirrol | |
| UY32153A (es) | Inhibidores de piridomidinona de pi13ka(alfa) y mtor | |
| AR085920A1 (es) | Derivados benzimidazolicos utiles como agentes antitumorales y composiciones farmaceuticas que los contienen | |
| AR092288A1 (es) | Ligandos del receptor ep1 | |
| AR070733A1 (es) | Derivados de platino-carbeno n-heterociclico, su preparacion, su composicion farmaceutica y su uso para el tratamiento del cancer | |
| AR081819A1 (es) | Derivados de pirimidil-piperidinil-oxipiridinona, composiciones farmaceuticas que los contienen y uso de los mismos para tratar diabetes, dislipemias, obesidad y otras enfermedades | |
| PH12014500669A1 (en) | Pharmaceutical compounds | |
| ES2650604T3 (es) | Nueva forma cristalina VII de agomelatina, método de preparación y utilización de la misma, así como composición farmacéutica que la contiene | |
| CO6280480A2 (es) | Ciclopentanos sustituidos que tienen actividad prostaglandina | |
| AR072880A1 (es) | Derivados nitrogenados de la pancratistatina | |
| AR054341A1 (es) | Combinaciones sinergicas de compuestos activos fungicidas |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration | ||
| FD | Application declared void or lapsed, e.g., due to non-payment of fee |